Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV

Journal of Gynecologic Oncology

Volumn 24, Issue 4, 2013, Pages 295-297

  Vinay Kumar, Ramaiah ^a   Bhasker, Suman ^b  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cervical cytologic screening; Developing countries; Gynecologic cancers; HPV typing; HPV vaccine

Indexed keywords

CANCER VACCINE;

AGE DISTRIBUTION; ARTICLE; CANCER MORTALITY; CANCER RISK; GYNECOLOGIC CANCER; HUMAN; IMMUNOGENICITY; MALNUTRITION; MORBIDITY; MULTIPARA; PERSISTENT INFECTION; PERSONAL HYGIENE; PUBLIC HEALTH; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; TOBACCO; UTERINE CERVIX CANCER; WART VIRUS;

EID: 84885618123     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2013.24.4.295     Document Type: Article

References (15)

1. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet 2012;380:2053-4.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Munoz N, Castellsague X, deGonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24 Suppl 3:S3/1-10.
4. Castellsague X, Diaz M, de Sanjose S, Munoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006;98:303-15.
5. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 2011;103:368-83.
6. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85.
7. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100-10.
8. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006;12(17 Suppl):S462-72.
9. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol 2007;197:566-71.
10. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
11. Madrid-Marina V, Torres-Poveda K, Lopez-Toledo G, Garcia Carranca A. Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res 2009;40:471-7.
12. PATH. Monitoring ambient and cold chain temperatures during delivery of human papillomavirus vaccine in Vietnam and Uganda. Seattle: World Health Organization, PATH; 2010.
13. World Health Organization. The world health report 2005: make every mother and child count. Geneva: World Health Organization; 2005.
14. Giard RW, Blok P. Cervical smears unsuitable for exclusion of cervical carcinoma. Ned Tijdschr Geneeskd 2000;144:86-7.
15. Castellsague X, Remy V, Puig-Tintore LM, de la Cuesta RS, Gonzalez-Rojas N, Cohet C. Epidemiology and costs of screening and management of precancerous lesions of the cervix in Spain. J Low Genit Tract Dis 2009;13:38-45.